Eli Lilly’s aggressive Taltz DTC advertising seems to be giving the new-to-market drug a boost in the next-generation psoriasis drug battle against Novartis' Cosentyx. While analyst Lynn Price was ...

Novartis knows that DTC advertising needs to be in the mix if it wants to "fully drive uptake" of the psoriasis-fighter in the U.S. And it's counting on its brand-new spot to get the ball rolling.

Cosentyx (secukinumab) is a prescription drug that’s used to treat conditions such as plaque psoriasis and psoriatic arthritis. Cosentyx is given as an injection under the skin or as an IV infusion.

Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients ...